Get the Stockscreener App
8.08
6.26%
-0.54
After Hours:
8.08
Wave Life Sciences Ltd stock is traded at $8.08, with a volume of 2.52M.
It is down -6.26% in the last 24 hours and down -23.56% over the past month.
See More
Previous Close:
$8.62
Open:
$8.27
24h Volume:
2.52M
Relative Volume:
2.65
Market Cap:
$1.55B
Revenue:
$53.61M
Net Income/Loss:
$-142.52M
P/E Ratio:
-7.2793
EPS:
-1.11
Net Cash Flow:
$-141.83M
1W Performance:
-19.76%
1M Performance:
-23.56%
6M Performance:
-1.46%
1Y Performance:
+30.96%
1-Day Range:
$7.92
$8.40
1-Week Range:
$7.92
$10.91
52-Week Range:
$4.25
$16.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
8.08 | 1.55B | 53.61M | -142.52M | -141.83M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Wave Life Sciences’ SWOT analysis: RNA editing pioneer faces challenges in genetic medicine stock - Investing.com India
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance
Promising Genomics & Synthetic Biology Stocks to Consider in 2025 - Yahoo Finance
HC Wainwright Reaffirms “Buy” Rating for Wave Life Sciences (NASDAQ:WVE) - Defense World
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531 (NASDAQ:WVE) - Seeking Alpha
WAVE Life Sciences stock holds buy rating, $22 target from H.C. Wainwright - Investing.com Australia
Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar? - Nasdaq
Wave Life Sciences reports progress in DMD treatment By Investing.com - Investing.com Australia
Wave Aspires To Accelerated Approval In DMD With 48-Week Data - insights.citeline.com
Riding the Wave, exon skipper sails toward DMD filing - BioWorld Online
Sector Update: Health Care Stocks Retreat Wednesday Afternoon - Marketscreener.com
Jefferies maintains Buy on WAVE Life Sciences stock, $26 target By Investing.com - Investing.com South Africa
Jefferies maintains Buy on WAVE Life Sciences stock, $26 target - Investing.com India
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year - Benzinga
Wave to seek FDA accelerated approval for Duchenne candidate in 2026 - MSN
Wave Life Sciences shares surge on positive DMD trial results By Investing.com - Investing.com Australia
Wave Life Sciences shares surge on positive DMD trial results - Investing.com
Wave Life Sciences reports progress in DMD treatment - Investing.com India
Wave Life Sciences Reports Positive Phase 2 Trial Results - TipRanks
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD - MarketScreener
Wave Life Sciences Announces Positive Data from FORWARD-53 - GlobeNewswire
Clinical Trial Breakthrough: New DMD Drug Achieves Unprecedented Muscle Recovery - StockTitan
Victory Capital Management Inc. Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Charles Schwab Investment Management Inc. Grows Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Wave Life Sciences director Christian Henry sells $102,574 in shares By Investing.com - Investing.com South Africa
Wave Life Sciences director Christian Henry sells $102,574 in shares - Investing.com
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Bank of New York Mellon Corp - Defense World
US Bancorp DE Cuts Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Arizona State Retirement System Acquires 7,846 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
How To Trade (WVE) - Stock Traders Daily
Wave Life Sciences’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year - Investing.com
Mizuho maintains WAVE Life Sciences Outperform rating - Investing.com India
Reviewing Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Paul Bolno Sells 169,025 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) Stock - Defense World
HC Wainwright Cuts Earnings Estimates for Wave Life Sciences - Defense World
Q1 EPS Forecast for Wave Life Sciences Decreased by Analyst - Defense World
Wave Life Sciences (NASDAQ:WVE) Rating Increased to Hold at StockNews.com - Defense World
Wave Life Sciences CEO Paul Bolno sells shares worth $1.62 million - Investing.com Australia
Commit To Purchase Wave Life Sciences At $7.50, Earn 25.6% Annualized Using Options - Nasdaq
Wave Life Sciences (NASDAQ:WVE) Earns “Buy” Rating from HC Wainwright - Defense World
Analysts Set Expectations for WVE Q1 Earnings - Defense World
H.C. Wainwright maintains $22 target on WAVE Life Sciences stock - Investing.com India
Wave Life Sciences’ Earnings Call Highlights Progress and Challenges - TipRanks
Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2024 Earnings Call Transcript - MSN
Truist maintains Buy rating on WAVE Life Sciences stock, $36 target By Investing.com - Investing.com South Africa
RBC Trims Price Target on Wave Life Sciences to $14 From $15, Keeps Sector Perform, Speculative Risk - Marketscreener.com
Rhumbline Advisers Buys 17,316 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
WAVE Life Sciences Ltd (WVE) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Clinical ... By GuruFocus - Investing.com Canada
Y Intercept Hong Kong Ltd Sells 6,875 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Principal Financial Group Inc. Buys Shares of 248,645 Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
WAVE Life Sciences Ltd (WVE) Q4 2024 Earnings Call Highlights: R - GuruFocus.com
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):